Concourse Financial Group Securities’s Sage Therapeutics SAGE Stock Holding History

Concourse Financial Group Securities’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,000	Closed	-$6.11K	–	2323
2024 Q3	$7.22K	Hold	1,000	–	–	﹤0.01%	1772
2024 Q2	$10.9K	Hold	1,000	–	–	﹤0.01%	1669
2024 Q1	$18.7K	Sell	1,000 -1	-0.1%	-$23	﹤0.01%	1525
2023 Q4	$21.7K	Hold	1,001	–	–	﹤0.01%	1466
2023 Q3	$20.6K	Buy	+1,001	New	+$28.9K	﹤0.01%	1427
2020 Q1	–	Sell	-93	Closed	-$5.38K	–	2294
2019 Q4	$7K	Buy	93 +18	+24%	+$2.21K	﹤0.01%	1549
2019 Q3	$11K	Sell	75 -20	-21%	-$3.35K	﹤0.01%	1131
2019 Q2	$17K	Sell	95 -8	-8%	-$1.36K	﹤0.01%	1312
2019 Q1	$16K	Buy	103 +1	+1%	+$145	﹤0.01%	1352
2018 Q4	$9K	Hold	102	–	–	﹤0.01%	1467
2018 Q3	$14K	Buy	+102	New	+$15.7K	﹤0.01%	989

Other funds holding SAGE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Concourse Financial Group Securities's SAGE Position: Q4 2024 in Review

Concourse Financial Group Securities sold out of Sage Therapeutics (SAGE) in Q4 2024, closing a stake of 1,000 shares — an estimated $6.11K sold.

Concourse Financial Group Securities first reported a position in SAGE in Q3 2018 and held it in 11 quarters. The position peaked at $21.7K in Q4 2023. 177 funds tracked by Wall St. Rank hold SAGE as of Q4 2024.

Concourse Financial Group Securities reported no remaining Sage Therapeutics position as of Q4 2024 after selling out during the quarter.
Concourse Financial Group Securities sold 1,000 Sage Therapeutics shares in Q4 2024, an estimated $6.11K.
Concourse Financial Group Securities first reported a position in Sage Therapeutics in Q3 2018 and held it in 11 quarters.
Concourse Financial Group Securities's Sage Therapeutics position peaked at $21.7K in Q4 2023.
177 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2024.

Based on Concourse Financial Group Securities's 13F filing for Q4 2024, filed 13 Feb 2025.